Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

INMD vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

INMD Overall Winner 6-Pillar Tally: INMD 3 – 3 DCTH Matrix Metrics: INMD 8 – 2 DCTH

As of Nov 16, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INMD carries a Unified Composite Score of 50.5/100 (HOLD) at $13.12 (9.8x Forward P/E, 17.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Growth vs. Quality Trade-Off: INMD earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. DCTH 35.9/100 SELL) and 0.59β · 35% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INMD vs DCTH
INMD NASDAQ Head-to-Head Winner
InMode Ltd. Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$13.12
-1.09% 1D
Market Cap $759.0M
TTM Revenue $374M
Forward P/E 9.8x
Beta / 30D Vol 0.59β · 35% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 41.0 Fund 54.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 40
RSI-14: 40.1 · SMA20: $13.62 · SMA50: $14.06
DCTH NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (INMD 3 – 3 DCTH)

Columns: Metric · INMD · DCTH
1. Valuation Multiples INMD
Forward P/E 9.8x N/M
Trailing P/E 10.9x 133.6x
PEG Ratio 2.90x 1.60x
EV / Revenue 1.0x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) -1.1% +70.7%
Earnings Growth (YoY) -5.9% +750.0%
TTM Revenue (USD) $374M $110M
Market Cap $759.0M $743.8M
3. Profitability & Quality INMD
Gross Margin 76.6% 87.6%
Operating Margin 17.6% 5.2%
Net Profit Margin 20.0% 6.0%
Return on Equity (ROE) 11.4% 5.4%
4. Balance Sheet & Cash Flow INMD
Cash Generation (TTM) $69M $20M
Cash Flow Margin 18.6% 18.3%
Net Cash / Leverage $394M Net Cash $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 36.5% (9th %ile) 109.3% (43rd %ile)
Put/Call OI Skew 0.74x (Call-Skewed) 0.11x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 59.0% of Rev ($220M) 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INMD (8) vs DCTH (2)
Institutional Metric INMD DCTH Criterion Row Edge
Market Capitalization
Scale
$759.0M $743.8M Larger Scale INMD
Trailing P/E Ratio
Valuation
10.9x 133.6x Lower Multiple INMD
Forward P/E Ratio
Valuation
9.8x N/M Lower Multiple INMD
Revenue Growth (YoY)
Growth
-1.1% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
17.6% 5.2% Higher Margin INMD
Net Profit Margin
Profitability
20.0% 6.0% Higher Margin INMD
Return on Equity (ROE)
Capital Efficiency
11.4% 5.4% Higher ROE INMD
52-Week Range Position
Momentum
10% ($13–$17) 80% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
0.59β · 35% Vol 1.63β · 131% Vol Lower Realized Risk INMD
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite INMD
Trailing 12M Revenue (USD)
Operating Scale
$374M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.6% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.90x PEG · 1.0x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$69M ($394M Net Cash) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +47.08 pp
INMD: -7.31% · DCTH: +39.77%
3M Horizon DCTH +29.17 pp
INMD: -12.44% · DCTH: +16.73%
6M Horizon DCTH +84.37 pp
INMD: -6.91% · DCTH: +77.46%
1Y Horizon DCTH +136.79 pp
INMD: -8.22% · DCTH: +128.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INMD Revenue DCTH Revenue INMD Op. Margin DCTH Op. Margin Margin Leader
FY2018 $100M N/A 23.5% N/A INMD
FY2019 $160M N/A 38.1% N/A INMD
FY2020 $210M N/A 35.3% N/A INMD
FY2021 $360M $0M 46.8% -690.0% INMD
FY2022 $450M $0M 43.6% -1245.1% INMD
FY2023 $490M $0M 39.8% -1849.0% INMD
FY2024 $390M $40M 28.5% -33.4% INMD
FY2025 $370M $90M 23.0% 0.8% INMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INMD CONSOLIDATION
86d in phase · OBV DISTRIBUTION
Current IV 36.5%
IV Percentile 9th %ile
Put/Call OI Skew 0.74x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact INMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INMD Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $759.0M market capitalization and 17.6% operating margin.
OpEx & R&D Reinvestment 59.0% of Rev ($220M)
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ INMD vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INMD carries a Unified Composite Score of 50.5/100 (HOLD) at $13.12 (9.8x Forward P/E, 17.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Growth vs. Quality Trade-Off: INMD earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. DCTH 35.9/100 SELL) and 0.59β · 35% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: INMD posts -1.1% YoY revenue growth and -5.9% YoY earnings growth on $374M TTM revenue (76.6% gross margin, 17.6% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INMD cumulative revenue shifted +270.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, INMD deploys 59.0% of Rev ($220M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

INMD screens cheaper on headline valuation multiples. INMD trades at 9.8x Forward P/E, 10.9x Trailing P/E, 2.90x PEG, and 1.0x EV/Revenue (18.6% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INMD (11.4% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, INMD carries 36.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.74x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 35% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.